Serge Bodart of IDDI provides insight on the pharma and biopharma trends impacting CROs, outsourcing in today’s market, and advances in clinical research.
The expansion, resulting from continued success and a year of growth across its key strategic partnerships, including top five pharmaceutical companies
Altasciences is a forward-thinking CRO for biopharma companies that recognize that time saved is opportunity gained, and opportunity gained is value realized.
IDDI, BMS Consortium aims to establish that the GPC statistical method can complement the design, analysis and interpretation of clinical trial results